Agios Pharmaceuticals reports Q4 EPS (40c), consensus (34c) Reports Q4 revenue $6.74M, consensus $6.19M. Agios expects to present initial clinical data from the dose escalation portion of the ongoing Phase 1 study of AG-221 at the 2014 American Association for Cancer Research Annual Meeting in early April. Agios expects to continue enrollment in its Phase 1 study of AG-221 and initiate expansion cohorts in late 2014. Agios plans to initiate two Phase 1 clinical trials for AG-120 in early 2014 in patients whose cancers carry an IDH1 mutation. These studies will leverage the clinical trial sites of Agiosí Phase 1 study of AG-221. Agios anticipates initiating single and multiple ascending dose-escalation studies for AG-348 in healthy volunteers in mid-2014. Agios expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements until late 2016.
Agios pyruvate kinase deficiency treatment granted FDA orphan status The FDA designated an allosteric activator of the red blood cell-specific form of pyruvate kinase from Agios Pharmaceuticals as an orphan treatment of pyruvate kinase deficiency, the FDA stated in a post to its site. Reference Link